FDA Approvals Roundup: Kloxxado, Farxiga, Ferriprox
The Pharma Data
MAY 5, 2021
It also provided supporting pharmacokinetic data demonstrating the opioid antagonist’s safety and efficacy. . Farxiga use expanded for reducing risks in patients with chronic kidney disease. The approval was based on results in a prespecified interim analysis of the first 264 patients of the ongoing KEYNOTE-811 trial.
Let's personalize your content